Janus Kinase Inhibitor Therapy for Cicatricial Alopecias: An Evidence-Based Review
- PMID: 39056418
- DOI: 10.1177/12034754241266153
Janus Kinase Inhibitor Therapy for Cicatricial Alopecias: An Evidence-Based Review
Keywords: JAK inhibitor; Janus kinase inhibitor; central centrifugal cicatricial alopecia; cicatricial alopecia; dissecting cellulitis of the scalp; evidence-based; folliculitis decalvans; frontal fibrosing alopecia; lichen planopilaris; scarring alopecia; systematic review.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Asfandyar Mufti has been a speaker for AbbVie and Janssen. Dr Jensen Yeung has been an advisor, consultant, speaker, and/or investigator for AbbVie, Allergan, Amgen, Astellas, Bausche, Baxalta, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Fresenius Kabi, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Xenon. The remaining authors Mr Sood, Mr Bagit, Ms Seeburruth, Dr Sachdeva, Dr Maliyar, Dr Abduelmula, and Dr Lyvtvn have no relevant disclosures.
Publication types
LinkOut - more resources
Full Text Sources
